In our previous studies, we showed that NPC2 downregulation is related to the development of nonalcoholic fatty liver disease, liver fibrosis, and hepatocellular carcinoma [21,23,24] Nevertheless, the effects of NPC2 expression and intracellular free cholesterol homeostasis on sorafenib sensitivity have not been explored in detail. Here, NPC2 is linked to metabolic dysfunction-associated steatotic liver disease.